Latest Rosiglitazone Stories
The Avandia lawyers at Onder, Shelton, Oâ€™Leary & Peterson, LLC have created a web site providing information about Avandia and how it has been linked to tens of thousands of heart attacks and strokes and the latest news on Avandia lawsuits Saint Louis, MO (Vocus) November 15, 2010 The law firm of Onder, Shelton, Oâ€™Leary & Peterson, LLC has launched a new website dedicated to providing information about Avandia heart attack and stroke lawsuits and are offering a free...
DEERFIELD, Ill. and LONDON, Sept. 23 /PRNewswire/ -- Following today's announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc.
European regulators say that widely-used diabetes drug Avandia should be pulled from the market, but US officials have allowed it to stay.
Makes regulatory decisions on RECORD and TIDE trials SILVER SPRING, Md., Sept. 23 /PRNewswire-USNewswire/ -- The U.S.
BURLINGTON, Mass., Sept.
FDA NOTE TO CORRESPONDENTS SILVER SPRING, Md., Sept. 17 /PRNewswire-USNewswire/ -- The U.S.
Study highlights: A new analysis of data on patients covered by a single insurance company reports that risks of heart disease events and death were no different between patients who took the diabetes drugs rosiglitazone or pioglitazone. In this analysis, approximately 4 percent of patients taking either drug - sold as Avandia and Actos - suffered a heart attack, heart failure, both or died over a 33-month period. See links below to the American Heart Association's statement on TZDs and...
Postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).